House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 6, 2015, Pages 843-855

  Calderón, Moisés A ^a   Kleine Tebbe, Jörg ^b   Linneberg, Allan ^c,d,e   De Blay, Frédéric ^f   Hernandez Fernandez de Rojas, Dolores ^g   Virchow, Johann Christian ^h   Demoly, Pascal ^i,j  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b Allergy and Asthma Center Westend   (Germany)

^c The Capital Region of Denmark   (Denmark)

^d GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^h ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

Allergen; Allergic asthma; Allergic rhinitis; Allergy; House dust mite; Respiratory allergic disease; Specific diagnosis; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; LEUKOTRIENE; NEDOCROMIL; OMALIZUMAB; THEOPHYLLINE; ALLERGEN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; COMPONENT RESOLVED DIAGNOSIS; DELAYED DIAGNOSIS; DIAGNOSTIC PROCEDURE; HOUSE DUST ALLERGY; HUMAN; META ANALYSIS; PREVENTION AND CONTROL; PRICK TEST; REVIEW; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TREATMENT REFUSAL; ANIMAL; DESENSITIZATION; HYPERSENSITIVITY; IMMUNOLOGY; PYROGLYPHIDAE; TREATMENT OUTCOME;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; PYROGLYPHIDAE; TREATMENT OUTCOME;

EID: 84946491173     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.06.019     Document Type: Review

References (150)

1. Blomme K., Tomassen P., Lapeere H., Huvenne W., Bonny M., Acke F., et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. Int Arch Allergy Immunol 2013, 160:200-207.
2. Arshad S.H. Does exposure to indoor allergens contribute to the development of asthma and allergy?. Curr Allergy Asthma Rep 2010, 10:49-55.
3. Calderón M.A., Linneberg A., Kleine-Tebbe J., de Blay F., Hernandez D., Virchow J.C., et al. Respiratory allergy due to house dust mites: what do we really know?. J Allergy Clin Immunol 2015, 136:38-48.
4. Andiappan A.K., Puan K.J., Lee B., Nardin A., Poidinger M., Connolly J., et al. Allergic airway diseases in a tropical urban environment are driven by dominant mono-specific sensitization against house dust mites. Allergy 2014, 69:501-509.
5. Biagtan M., Viswanathan R., Bush R.K. Immunotherapy for house dust mite sensitivity: where are the knowledge gaps?. Curr Allergy Asthma Rep 2014, 14:482.
6. Gandhi V.D., Davidson C., Asaduzzaman M., Nahirney D., Vliagoftis H. House dust mite interactions with airway epithelium: role in allergic airway inflammation. Curr Allergy Asthma Rep 2013, 13:262-270.
7. 2LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160.
8. Pfaar O., Bachert C., Bufe A., Buhl R., Ebnerg C., Eng P., et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases. Allergo J Int 2014, 23:282-319.
9. Calderón M.A., Casale T.B., Nelson H.S., Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013, 132:1322-1336.
10. Burks A.W., Calderón M.A., Casale T., Cox L., Demoly P., Jutel M., et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013, 131:1288-1296.
11. Cox L., Nelson H., Lockey R., Calabria C., Chacko T., Finegold I., et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127:S1-S55.
12. Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008, 122:S1-S84.
13. US Department of Health and Human Services. National Heart, Lung, and Blood Institute National Asthma Education and Prevention Program (NAEPP). Busse WW, Boushey HA, Camargo CA, Evans D, Foggs MB, Janson SL et al. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report; 2007. National Heart, Lung and Blood Institute, Bethesda MD.
14. Canonica G.W., Bousquet J., Casale T., Lockey R.F., Baena-Cagnani C.E., Pawankar R., et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64(Suppl 91):1-59.
15. 2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010, 65:1525-1530.
16. Papadopoulos N.G., Bernstein J.A., Demoly P., Dykewicz M., Fokkens W., Hellings P.W., et al. Phenotypes & endotypes of rhinitis and their impact on management: a PRACTALL report Allergy 2015, 70:474-494.
17. Warner J.O., Kaliner M.A., Crisci C.D., Del Giacco S., Frew A.J., Liu G.H., et al. World Allergy Organization Specialty and Training Council. Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol 2006, 139:166-174.
18. Pfaar O., Demoly P., Gerth van Wijk R., Bonini S., Bousquet J., Canonica G.W., et al. European Academy of Allergy and Clinical Immunology. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014, 69:854-867.
19. Berthold M. A molecular approach to allergy diagnosis. Immuno Diagnostics J 2014, 1:4-11.
20. Melioli G., Compalati E., Bonini S., Canonica G.W. The added value of allergen microarray technique to the management of poly-sensitized allergic patients. Curr Opin Allergy Clin Immunol 2012, 12:434-439.
21. Valenta R., Lidholm J., Niederberger V., Hayek B., Kraft D., Gronlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999, 29:896-904.
22. Akdis C.A., Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011, 127:18-27.
23. Valenta R., Linhart B., Swoboda I., Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011, 66:775-783.
24. Calderón M.A., Cox L., Casale T.B., Moingeon P., Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012, 129:929-934.
25. Bahceciler N.N., Galip N., Cobanoglu N. Multiallergen-specific immunotherapy in polysensitized patients: where are we?. Immunotherapy 2013, 5:183-190.
26. Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., Casale T.B., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2010 revision. J Allergy Clin Immunol 2010, 126:466-476.
27. Gøtzsche P.C., Johansen K.H. House dust mite control measures for asthma: systematic review. Allergy 2008, 63:646-659.
28. Nurmatov U., van Schayck C.P., Hurwitz B., Sheikh A. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy 2012, 67:158-165.
29. Morgan W.J., Crain E.F., Gruchalla R.S., O'Connor G.T., Kattan M., Evans R., et al. Inner-city results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004, 351:1068-1080.
30. Krieger J., Jacobs D.E., Ashley P.J., Baeder A., Chew G.L., Dearborn D., et al. Housing interventions and control of asthma-related indoor biologic agents: a review of the evidence. J Public Health Manag Pract 2010, 16:S11-S20.
31. Toelle B.G., Ng K.K., Crisafulli D., Belousova E.G., Almqvist C., Webb K., et al. Childhood Asthma Prevention Team. Eight-year outcomes of the Childhood Asthma Prevention Study. J Allergy Clin Immunol 2010, 126:388-389. 389.e1-3.
32. Maurer M., Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007, 62:1057-1063.
33. Cox L., Compalati E., Kundig T., Larche M. New directions in immunotherapy. Curr Allergy Asthma Rep 2013, 13:178-195.
34. Canonica G.W., Cox L., Pawankar R., Baena-Cagnani C.E., Blaiss M., Bonini S., et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014, 7:6.
35. Moingeon P. Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines 2014, 13:1463-1473.
36. Nelson H.S. Update on house dust mite immunotherapy: are more studies needed?. Curr Opin Allergy Clin Immunol 2014, 14:542-548.
37. De Blay F., Kuna P., Prieto L., Ginko T., Seitzberg D., Riis B., et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma-post hoc results from a randomised trial. Respir Med 2014, 108:1430-1437.
38. Mosbech H., Deckelmann R., de Blay F., Pastorello E.A., Trebas-Pietras E., Andres L.P., et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014, 134:568-575.e7.
39. Corren J. Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med 2013, 15:243-249.
40. Agache I.O. From phenotypes to endotypes to asthma treatment. Curr Opin Allergy Clin Immunol 2013, 13:249-256.
41. Haldar P., Pavord I.D., Shaw D.E., Berry M.A., Thomas M., Brightling C.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
42. Feng C.H., Miller M.D., Simon R.A. The united allergic airway: connections between allergic rhinitis, asthma, and chronic sinusitis. Am J Rhinol Allergy 2012, 26:187-190.
43. Shekelle P.G., Woolf S.H., Eccles M., Grimshaw J. Clinical guidelines - developing guidelines. BMJ 1999, 318:593-596.
44. Cox L., Nelson H., Lockey R. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127:S1-S55.
45. Jaén A., Sunyer J., Basagaña X., Zock J.P., Anto J.M., Burney P. Specific sensitization to common allergens and pulmonary function in the European Community Respiratory Health Survey. Clin Exp Allergy 2002, 32:1713-1719. European Community Respiratory Health Survey.
46. Langley S.J., Goldthorpe S., Craven M., Woodcock A., Custovic A. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitized, atopic asthmatic subjects. Thorax 2005, 60:17-21.
47. Kanchongkittiphon W., Mendell M.J., Gaffin J.M., Wang G., Phipatanakul W. Indoor environmental exposures and exacerbation of asthma: an update to the 2000 review by the Institute of Medicine. Environ Health Perspect 2015, 123:6-20.
48. Gent J.F., Belanger K., Triche E.W., Bracken M.B., Beckette W.S., Leaderer B.P. Association of pediatric asthma severity with exposure to common household dust allergens. Environ Res 2009, 109:768-774.
49. Kovac K., Dodig S., Tjesić-Drinković D., Raos M. Correlation between asthma severity and serum IgE in asthmatic children sensitized to Dermatophagoides pteronyssinus. Arch Med Res 2007, 38:99-105.
50. Zureik M., Neukirch C., Béné Leynaert B., Liard R., Bousquet J., Neukirch F. Sensitization to airborne moulds and severity of asthma: cross sectional study from European Community Respiratory Health Survey. BMJ 2002, 325:411-414. on behalf of the European Community Respiratory Health Survey.
51. ten Brinke A., Sterk P.J., Masclee A.A., Spihoven P., Schmidt J.T., Zwinderman A.H., et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J January 21, 2014, 2005(26):812-818.
52. Linneberg A., Henrik Nielsen N., Frølund L., Madsen F., Dirksen A., Jørgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002, 57:1048-1052. Copenhagen Allergy Study.
53. Lin J., Su N., Liu G., Yin K., Zhou X., Shen H., et al. The impact of concomitant allergic rhinitis on asthma control: a cross-sectional nationwide survey in China. J Asthma 2014, 51:34-43.
54. Magnan A., Meunier J.P., Saugnac C., Gasteau J., Neukirch F. Frequency and impact of allergic rhinitis in asthma patients in everyday general medical practice: a French observational cross-sectional study. Allergy 2008, 3:292-298.
55. Kupczyk M., Wenzel S. U.S. and European severe asthma cohorts: what can they teach us about severe asthma?. J Intern Med 2012, 272:121-132.
56. Bauchau V., Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004, 24:758-764.
57. Chivato T., Valovirta E., Dahl R., de Monchy J., Bloch Thomsen A., Palkonen S., et al. Allergy, living and learning: diagnosis and treatment of allergic respiratory diseases in Europe. J Investig Allergol Clin Immunol 2012, 22:168-179.
58. Lehman J.M., Blaiss M.S. Selecting the optimal oral antihistamine for patients with allergic rhinitis. Drugs 2006, 66:2309-2319.
59. Bachert C., Bousquet J., Canonica G.W., Durham S.R., Klimek L., Mullol J., et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004, 114:838-844. XPERT Study Group.
60. Stübner P., Zieglmayer R., Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit - the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004, 20:891-902.
61. Kennedy J.L., Heymann P.W., Platts-Mills T.A. The role of allergy in severe asthma. Clin Exp Allergy 2012, 42:659-669.
62. Corren J., Shapiro G., Reimann J., Deniz Y., Wong D., Adelman D., et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008, 121:506-511.
63. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001, 108:E36.
64. Cloosterman S.G., Bijl-Hofland I.D., van Herwaarden C.L., Akkermans R.P., van Den Elshout F.J., Folgering H.T., et al. A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta (2)-agonists in allergic asthmatic patients. Chest 2001, 119:1306-1315.
65. Albano P.M., Ramos J.D.A. Association of house dust mite-specific IgE with asthma control, medications and household pets. Asia Pac Allergy 2011, 1:145-151.
66. Hatchwell L., Girkin J., Dun M.D., Morten M., Verrills N., Toop H.D., et al. Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A. J Allergy Clin Immunol 2014, 133:1720-1727.
67. Johnson J.R., Pacitto S.R., Wong J., Archer E.W., Eirefelt S., Miller-Larsson A., et al. Combined budesonide/formoterol therapy in conjunction with allergen avoidance ameliorates house dust mite-induced airway remodeling and dysfunction. Am J Physiol Lung Cell Mol Physiol 2008, 295:L780-L788.
68. Stubner U.P., Toth J., Marks B., Berger U.E., Burtin B., Horak F. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus xylometazoline nasal spray in nasal congestion. Arzneimittelforschung 2001, 51:904-910.
69. Zieglmayer U.P., Horak F., Toth J., Marks B., Berger U.E., Burtin B. Efficacy and safety of an oral formulation of cetirizine and prolonged-release pseudoephedrine versus budesonide nasal spray in the management of nasal congestion in allergic rhinitis. Treat Respir Med 2005, 4:283-287.
70. Al Sayyad J.J., Fedorowicz Z., Alhashimi D., Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev 2007, (1):CD003163. Accessed September 28, 2014.
71. Kessel A., Halloun H., Bamberger E., Kugelman A., Toubi E. Abnormal spirometry in children with persistent allergic rhinitis due to mite sensitization: the benefit of nasal corticosteroids. Pediatr Allergy Immunol 2008, 19:61-66.
72. Ulrich K., Hincks J.S., Walsh R., Wetterstrand E.M., Fidock M.D., Sreckovic S., et al. Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model. Pulm Pharmacol Ther 2008, 21:637-647.
73. Obase Y., Shimoda T., Tomari S., Mitsuta K., Kawano T., Matsuse H., et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002, 121:143-150.
74. Stelmach I., Majak P., Jerzynska J., Stelmach W., Kuna P. Comparative effect of triamcinolone, nedocromil and montelukast on asthma control in children: a randomized pragmatic study. Pediatr Allergy Immunol 2004, 15:359-364.
75. Kimura M., Okafuji I., Yoshida T. Theophylline suppresses IL-5 and IL-13 production, and lymphocyte proliferation upon stimulation with house dust mite in asthmatic children. Int Arch Allergy Immunol 2003, 131:189-194.
76. Valovirta E., Lheritier-Barrand M., Tauleigne L., David M., Lemonnier L., Rolland C. Patients' perceptions and experience of house dust mite allergy in a European survey. Eur Respir Dis 2012, 8:123-128.
77. Nolte H., Nepper-Christensen S., Backer V. Unawareness and undertreatment of asthma and allergic rhinitis in a general population. Respir Med 2006, 100:354-362.
78. Shaaban R., Zureik M., Soussan D., Neukirch C., Heinrich J., Sunyer J., et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008, 372:1049-1057.
79. Leynaert B., Neukirch F., Demoly P., Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000, 106:S201-S205.
80. Boulay M.E., Morin A., Laprise C., Boulet L.P. Asthma and rhinitis: what is the relationship?. Curr Opin Allergy Clin Immunol 2012, 12:449-454.
81. Global Initiative for Asthma (GINA). Pocket guide for asthma management and prevention: for adults and children older than 5 years. 2012. Developed from Global Strategy for Asthma Management and Prevention (Reference 112.) Available from Accessed May 11, 2015. http://www.ginasthma.org/documents/2/documents_variants/38.
82. Demoly P., Calderón M.A., Casale T., Scadding G., Annesi-Maesano I., Braun J.J., et al. Assessment of disease control in allergic rhinitis. Clin Transl Allergy 2013, 3:7.
83. Agache I., Ryan D., Rodriguez M.R., Yusuf O., Angier E., Jutel M. Allergy management in primary care across European countries - actual status. Allergy 2013, 68:836-843.
84. De Monchy J.G., Demoly P., Akdis C.A., Cardona V., Papadopoulos N.G., Schmid-Grendelmeier P., et al. Allergology in Europe, the blueprint. Allergy 2013, 68:1211-1218.
85. Stewart M.G. Identification and management of undiagnosed and undertreated allergic rhinitis in adults and children. Clin Exp Allergy 2008, 38:751-760.
86. Williams A., Scadding G. Is reliance on self-medication and pharmacy care adequate for rhinitis patients?. Int J Clin Pract 2009, 63:98-104.
87. Canonica G.W., Bousquet J., Mullol J., Scadding G.K., Virchow J.C. A survey of the burden of allergic rhinitis in Europe. Allergy 2007, 62(Suppl 85):17-25.
88. Santos C.B., Pratt E.L., Hanks C., McCann J., Craig T.J. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol 2006, 97:579-586. quiz 586-9, 671.
89. Bousquet J., Neukirch F., Bousquet P.J., Gehano P., Klossek J.M., Le Gal M., et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006, 117:158-162.
90. Lamb C.E., Ratner P.H., Johnson C.E., Ambegaonkar A.J., Joshi A.V., Day D., et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006, 22:1203-1210.
91. Blaiss M.S. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004, 20:1937-1952. Allergic Rhinitis in Schoolchildren Consensus Group.
92. Walker S., Khan-Wasti S., Fletcher M., Cullinan P., Harris J., Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 2007, 120:381-387.
93. Marshall P.S., O'Hara C., Steinberg P. Effects of seasonal allergic rhinitis on fatigue levels and mood. Psychosom Med 2002, 64:684-691.
94. Sansone R.A., Sansone L.A. Allergic rhinitis: relationships with anxiety and mood syndromes. Innov Clin Neurosci 2011, 8:12-17.
95. Bavbek S., Kumbasar H., Tuğcu H., Misirligil Z. Psychological status of patients with seasonal and perennial allergic rhinitis. J Investig Allergol Clin Immunol 2002, 12:204-210.
96. Loh C.Y., Chao S.S., Chan Y.H., Wang D.Y. A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy 2004, 59:1168-1172.
97. Demoly P., Allaert F.A., Lecasble M., Klossek J.M. ERAP, a pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France. Presse Med 2003, 32:1066-1073. Groupe Pragma, [in French].
98. Hellings P.W., Fokkens W.J., Akdis C., Bachert C., Cingi C., Dietz de Loos D., et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?. Allergy 2013, 68:1-7.
99. Valero A., Justicia J.L., Vidal C., Rodríguez V., Muñoz R., García M.A. Diagnosis and treatment of allergic rhinitis due to house-dust mites in Spain. Am J Rhinol Allergy 2012, 26:23-26.
100. Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006, 6:13.
101. Weghofer M., Grote M., Resch Y., Casset A., Kneidinger M., Kopec J., et al. Identification of Der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol 2013, 190:3059-3067.
102. Ferreira F., Hawranek T., Gruber P., Wopfner N., Mari A. Allergic cross-reactivity: from gene to the clinic. Allergy 2004, 59:243-267.
103. Weghofer M., Thomas W.R., Kronqvist M., Mari A., Purohit A., Pauli G., et al. Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest 2008, 38:959-965.
104. 2LEN network. Allergy 2005, 60:1287-1300.
105. Bousquet J., Heinzerling L., Bachert C., Papadopoulos N.G., Bousquet P.J., Burney P.G., et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2012, 67:18-24.
106. Fatteh S., Rekkerth D.J., Hadley J.A. Skin prick/puncture testing in North America: a call for standards and consistency. Allergy Asthma Clin Immunol 2014, 10:44.
107. van Kampen V., de Blay F., Folletti I., Kobierski P., Moscato G., Olivieri M., et al. EAACI position paper: skin prick testing in the diagnosis of occupational type I allergies. Allergy 2013, 68:580-584.
108. Schram-Bijkerk D., Doekes G., Boeve M., Douwes J., Riedler J., Ublagger E., et al. Nonlinear relations between house dust mite allergen levels and mite sensitization in farm and nonfarm children. Allergy 2006, 61:640-647.
109. Torrent M., Sunyer J., Munoz L., Cullinan P., Iturriaga M.V., Figueroa C., et al. Early-life domestic aeroallergen exposure and IgE sensitization at age 4 years. J Allergy Clin Immunol 2006, 118:742-748.
110. Cullinan P., MacNeill S.J., Harris J.M., Moffat S., White C., Mills P., et al. Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: a cohort study. Thorax 2004, 59:855-861.
111. Tovey E.R., Marks G.B. It's time to rethink mite allergen avoidance. J Allergy Clin Immunol 2011, 128:723-727.e6.
112. Reddel H, Barnes N, Barnes PJ, Bateman ED, Becker A, Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2012. Available from http://www.ginasthma.org/documents/5/documents_variants/37.
113. 2LEN). Allergy 2005, 60:1112-1115.
114. Nankervis H., Pynn E.V., Boyle R.J., Rushton L., Williams H.C., Hewson D.M., et al. House dust mite reduction and avoidance measures for treating eczema. Cochrane Database Syst Rev 2015, (1):CD008426.
115. Pingitore G., Pinter E. Environmental interventions for mite-induced asthma: a journey between systematic reviews, contrasting evidence and clinical practice. Eur Ann Allergy Clin Immunol 2013, 45:74-77.
116. Platts-Mills T.A. Allergen avoidance in the treatment of asthma: problems with the meta-analyses. J Allergy Clin Immunol 2008, 122:694-696.
117. Jadad A.R., Moher M., Browman G.P., Booker L., Sigouin C., Fuentes M., et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. BMJ 2000, 26:537-540.
118. Schmidt L.M., Gotzsche P.C. Of mites and men: reference bias in narrative review articles: a systematic review. J Fam Pract 2005, 54:334-338.
119. Crocker D.D., Kinyota S., Dumitru G.G., Ligon C.B., Herman E.J., Ferdinands J.M., et al. Effectiveness of home-based, multi-trigger, multicomponent interventions with an environmental focus for reducing asthma morbidity: a community guide systematic review. Am J Prev Med 2011, 41:S5-S32. Task Force on Community Preventive Services.
120. Roberts G., Xatzipsalti M., Borrego L.M., Custovic A., Halken S., Hellings P.W., et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy 2013, 68:1102-1116.
121. De Blay F., Fourgaut G., Hedelin G., Vervloet D., Michel F.B., Goddard P., et al. Medical Indoor Environment Counselor (MIEC): role in compliance with advice on mite allergen avoidance and on mite allergen exposure. Allergy 2003, 58:27-33. Scientific Committee of the MIEC study.
122. MacDonald C., Sternberg A., Hunter P.R. A systematic review and meta-analysis of interventions used to reduce exposure to house dust and their effect on the development and severity of asthma. Environ Health Perspect 2007, 115:1691-1695.
123. Woodcock A., Lowe L.A., Murray C.S., Simpson B.M., Pipis S.D., Kissen P., et al. Early life environmental control effect on symptoms, sensitization, and lung function at age 3 Years. Am J Respir Crit Care Med 2004, 170:433-439. on behalf of the NAC Manchester Asthma and Allergy Study Group.
124. Scott M., Roberts G., Kurukulaaratchy R.J., Matthews S., Nove A., Arshad S.H. Multifaceted allergen avoidance during infancy reduces asthma during childhood with the effect persisting until age 18 years. Thorax 2012, 67:1046-1051.
125. Arshad S.H., Bateman B., Sadeghnejad A., Gant C., Matthews S.M. Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. J Allergy Clin Immunol 2007, 119:307-313.
126. Becker A., Watson W., Ferguson A., Dimich-Ward H., Chan-Yeung M. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol 2004, 113:650-656.
127. Chan-Yeung M., Ferguson A., Watson W., Dimich-Ward H., Rousseau R., Lilley M., et al. The Canadian Childhood Asthma Primary Prevention Study: outcomes at 7 years of age. J Allergy Clin Immunol 2005, 116:49-55.
128. Halken S. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention. Pediatr Allergy Immunol 2004, 15(Suppl 16):4-5. 9-32.
129. Tovey E., Ferro A. Time for new methods for avoidance of house dust mite and other allergens. Curr Allergy Asthma Rep 2012, 12:465-477.
130. Simpson A., Tan V.Y.F., Winn J., Svensen M., Bishop C.M., Heckerman D.E., et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. Am J Respir Crit Care Med 2010, 181:1200-1206.
131. Morris A.E., Marshall G.D. Safety of allergen immunotherapy: a review of premedication and dose adjustment. Immunotherapy 2012, 4:315-322.
132. Baron-Bodo V., Batard T., Nguyen H., Fréreux M., Horiot S., Harwanegg C., et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy 2012, 42:1510-1518.
133. Lin S.Y., Erekosima N., Kim J.M., Ramanathan M., Suarez-Cuervo C., Chelladurai Y., et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013, 309:1278-1288.
134. Linhart B., Valenta R. Vaccines for allergy. Curr Opin Immunol 2012, 24:354-360.
135. Calderón M.A., Carr V.A., Jacobson M., Sheikh A., Durham S. Allergen injection immunotherapy for perennial allergic rhinitis. Cochrane Database Syst Rev 2008, (2):CD007163.
136. Radulovic S., Calderón M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010, (12):CD002893.
137. Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010, (8):CD001186.
138. Calamita Z., Saconato H., Pelu A.B., Atallah N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy 2006, 61:1162-1172. Accessed May 15, 2015.
139. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003, 33:206-210.
140. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol 2009, 9:168-176.
141. Sopo S.M., Macchiaiolo M., Zorzi G., Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis: systematic review of paediatric literature. Arch Dis Child 2004, 89:620-624. Accessed May 15, 2015.
142. Hoeks S.B., de Groot H., Hoekstra M.O. Sublingual immunotherapy in children with asthma or rhinoconjunctivitis: not enough evidence because of poor quality of the studies; a systematic review of literature. Ned Tijdschr Geneeskd 2008, 152:261-268. [in Dutch], Information from English abstract.
143. Larenas-Linnemann D., Blaiss M., Van Bever H.P., Compalati E., Baena-Cagnani C.E. Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Ann Allergy Asthma Immunol 2013, 110:402-415.e9.
144. Calderón M.A., Boyle R.J., Penagos M., Sheikh A. Immunotherapy: the meta-analyses. What have we learned?. Immunol Allergy Clin North Am 2011, 31:159-173. vii.
145. Wilson D.R., Lima M.T., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60:4-12.
146. Bronnert M., Mancini J., Birnbaum J., Agabriel C., Liabeuf V., Porri F., et al. Component-resolved diagnosis with commercially available D. pteronyssinus Der p 1, Der p 2 and Der p 10: relevant markers for house dust mite allergy. Clin Exp Allergy 2012, 42:1406-1415.
147. Marogna M., Spadolini I., Massolo A., Canonica G.W., Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010, 126:969-975.
148. Li P., Li Q., Huang Z., Chen W., Lu Y., Tian M. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol 2014, 4:796-801.
149. Lee J.E., Choi Y.S., Kim M.S., Han D.H., Rhee C.S., Lee C.H., et al. Efficacy of sublingual immunotherapy with house dust mite extract in polyallergen sensitized patients with allergic rhinitis. Ann Allergy Asthma Immunol 2011, 107:79-84.
150. Nelson H.S. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009, 123:763-769.